Education
About Us
Working with TipRanks
Follow Us
Ironwood Pharma (IRWD)
NASDAQ:IRWD
IRWD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.59 - $8.23
Previous CloseN/A
Volume359.32K
Average Volume (3M)3.50M
Market Cap
$150.85M
Enterprise Value$1.22B
Total Cash (Recent Filing)$74.30M
Total Debt (Recent Filing)$177.32M
Price to Earnings (P/E)85.8
Beta0.68
Next Earnings
Aug 07, 2025EPS Estimate
>-0.01Last Dividend Ex-Date
Apr 02, 2019Dividend YieldN/A
Share Statistics
EPS (TTM)-0.23
Shares Outstanding161,809,430
10 Day Avg. Volume2,431,904
30 Day Avg. Volume3,500,672
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap8.10
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.61
Enterprise Value/Ebitda11.51
Forecast
1Y Price Target
$0.90Price Target Upside-3.23% Downside
Rating ConsensusHold
Number of Analyst Covering6
---
Bulls Say, Bears Say
Bulls Say
Earnings GuidanceIRWD raised FY25 Adjusted EBITDA guidance by ~$20M to $105M+ driven by expectation of lower commercial spend related to the Apra launch.
Strategic OptionsIronwood Pharmaceuticals is exploring strategic options such as partnerships and mergers, indicating potential challenges in its current strategy.
Bears Say
Debt And Cash FlowThe high debt load and delay in apraglutide's revenue contribution mean there will likely be no meaningful revenue contribution until after Linzess' loss of exclusivity and debt maturity.
Financial UncertaintyAn additional confirmatory Phase 3 trial for apraglutide in short bowel syndrome is needed for approval, adding financial uncertainty to the company.
Revenue Impact1Q25 US Linzess revenues of ~$139M (-45% y/y) primarily reflects headwind from change in ABBVs GtN rebate reserves estimates.
---
Ownership Overview
13.05% Insiders
17.08% Mutual Funds
0.23% Other Institutional Investors
50.95% Public Companies and
Individual Investors
IRWD FAQ
What was Ironwood Pharma’s price range in the past 12 months?
Ironwood Pharma lowest stock price was $0.59 and its highest was $8.23 in the past 12 months.
What is Ironwood Pharma’s market cap?
Ironwood Pharma’s market cap is $150.85M.
When is Ironwood Pharma’s upcoming earnings report date?
Ironwood Pharma’s upcoming earnings report date is Aug 07, 2025 which is in 91 days.
How were Ironwood Pharma’s earnings last quarter?
Ironwood Pharma released its earnings results on May 01, 2025. The company reported -$0.23 earnings per share for the quarter, missing the consensus estimate of -$0.136 by -$0.094.
Is Ironwood Pharma overvalued?
According to Wall Street analysts Ironwood Pharma’s price is currently Overvalued.
Does Ironwood Pharma pay dividends?
Ironwood Pharma pays a Notavailable dividend of $2.285 which represents an annual dividend yield of N/A. See more information on Ironwood Pharma dividends here
What is Ironwood Pharma’s EPS estimate?
Ironwood Pharma’s EPS estimate is >-0.01.
How many shares outstanding does Ironwood Pharma have?
Ironwood Pharma has 161,809,430 shares outstanding.
What happened to Ironwood Pharma’s price movement after its last earnings report?
Ironwood Pharma reported an EPS of -$0.23 in its last earnings report, missing expectations of -$0.136. Following the earnings report the stock price went down -2.151%.
Which hedge fund is a major shareholder of Ironwood Pharma?
Currently, no hedge funds are holding shares in IRWD
---
Ironwood Pharma Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$0.90 (-3.23% Downside)
$0.90 (-3.23% Downside)
Blogger Sentiment
Bullish
IRWD Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 52.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $428.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.4%
Last 30 Days ▲ 4.1%
Last 30 Days ▲ 4.1%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-88.58%
12-Months-Change
Fundamentals
Return on Equity
-8.02%
Trailing 12-Months
Asset Growth
-25.51%
Trailing 12-Months
Company Description
Ironwood Pharma
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
---
IRWD Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strong demand growth for LINZESS and promising data for apraglutide, suggesting potential future growth. However, concerns about pricing headwinds from Medicare Part D redesign and cash liquidity tempered the overall outlook.Read More>---
IRWD Stock 12 Month Forecast
Average Price Target
$0.90
▼(-3.23% Downside)
Technical Analysis
Assertio Therapeutics
―
Esperion
―
Cumberland Pharmaceuticals
―
Aquestive Therapeutics
―
Journey Medical Corp
―
---